At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 383 enrolled
Drug / intervention
TA-7284-Low +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Dose-Ranging Study in Subjects With Type 2 Diabetes Mellitus to Evaluate the Efficacy, Safety, and Tolerability of Orally-Administered SGLT2 Inhibitor TA-7284
In Brief
A Phase 2 clinical trial evaluating TA-7284-Low, TA-7284-Low-middle, and 3 other interventions for Type 2 Diabetes Mellitus. Completed, enrolled 383 participants across 6 sites.
Detailed Summary
The purpose of this study is to demonstrate the efficacy, safety, and tolerability of TA-7284 compared with placebo in patients with type 2 diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2009
First PostedDec 2009
Primary CompletionSep 2010
TodayJul 2026
First PostedDec 1, 2009
Enrollment StartNov 1, 2009
Primary CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 16.6 years ago
Interventions
TA-7284-Lowdrug
TA-7284-Low
TA-7284-Low-middledrug
TA-7284-Low-middle
TA-7284-High-middledrug
TA-7284-High-middle
TA-7284-Highdrug
TA-7284-High
Placebodrug
Placebo